Download FREE Report Sample
Download Free samplePulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
Pulmonary Fibrosis Drug Market contains market size and forecasts of Pulmonary Fibrosis Drug in global, including the following market information:
Global Pulmonary Fibrosis Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Pulmonary Fibrosis Drug Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Pulmonary Fibrosis Drug companies in 2021 (%)
The global Pulmonary Fibrosis Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Pirfenidone Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Fibrosis Drug include Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc. and Biogen and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Pulmonary Fibrosis Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Fibrosis Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pulmonary Fibrosis Drug Market Segment Percentages, by Type, 2021 (%)
Pirfenidone
Nintedanib
Global Pulmonary Fibrosis Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pulmonary Fibrosis Drug Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Global Pulmonary Fibrosis Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pulmonary Fibrosis Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Fibrosis Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Pulmonary Fibrosis Drug revenues share in global market, 2021 (%)
Key companies Pulmonary Fibrosis Drug sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Pulmonary Fibrosis Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boehringer Ingelheim
Roche
FibroGen, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
MediciNova, Inc.
Genentech, Inc.
Cipla Inc.
Biogen
Galapagos NV
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
